Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.000
-0.010 (-0.33%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$699,884
Profits / Employee
$522
Market Cap
16.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
LPCN News
- 24 days ago - Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PRNewsWire
- 5 weeks ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - PRNewsWire
- 5 weeks ago - Lipocine Announces FDA Labeling Changes for Testosterone Products - PRNewsWire
- 2 months ago - Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - PRNewsWire
- 4 months ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 5 months ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 5 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 6 months ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire